Haleon (HLN) Net Income towards Common Stockholders (2021 - 2025)
Haleon's (HLN) quarterly Net Income towards Common Stockholders came in at $1.1 billion in Q4 2025, up 26.65% on a QoQ basis from $852.7 million in Q4 2023.
Haleon (HLN) Net Income towards Common Stockholders (2021 - 2025) Analysis & Trends
Haleon (HLN) has 4 years of Net Income towards Common Stockholders data on file, last reported at $1.1 billion in Q4 2025.
- Quarterly Net Income towards Common Stockholders changed N/A year-over-year to $1.1 billion in Q4 2025, while the trailing twelve-month figure through Jun 2026 was $1.1 billion (changed N/A YoY) and the FY2025 annual result came in at $2.2 billion, up 20.3% from the prior year.
- Net Income towards Common Stockholders improved to $1.1 billion in Q4 2025, from $852.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $1.2 billion in Q4 2021 to a low of $372.9 million in Q2 2023.
- A 4-year average of $798.7 million and a median of $852.7 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders fell 12.99% — and 2023, when it dropped 15.67%.
- Tracing HLN's Net Income towards Common Stockholders over 4 years: stood at $1.2 billion in 2021, then retreated by 12.99% to $1.0 billion in 2022, then slipped by 15.67% to $852.7 million in 2023, then rose by 26.65% to $1.1 billion in 2025.
- The last three Net Income towards Common Stockholders figures came in at $1.1 billion (Q4 2025), $852.7 million (Q4 2023), and $372.9 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.08 Bn |
| Dec 31, 2023 | 852.67 Mn |
| Jun 30, 2023 | 372.91 Mn |
| May 3, 2023 | 475.66 Mn |
| Dec 31, 2022 | 1.01 Bn |
| Sep 20, 2022 | 636.58 Mn |
| Dec 31, 2021 | 1.16 Bn |